IL6 and prostate cancer: In CSCs, the IL-6/gp130/STAT3 signaling pathway has been demonstrated to be involved in the regulation of CSC properties such as self-renewal, stemness marker expression, and tumor cell growth in prostate cancer [22], glioma [23], endometrial cancer [24], and breast cancer [25].